World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
52881
World Ranking
15840
National Ranking
7970

Overview

Paul B. Chapman is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily lies at the intersection of medicine and biochemistry, genetics, and molecular biology, with a strong focus on oncology, molecular biology, immunology, genetics, and cancer research.

Their scientific work revolves around several key topics including CAR-T cell therapy research, cancer immunotherapy and biomarkers, melanoma and MAPK pathways, immunotherapy and immune responses, cutaneous melanoma detection and management, cancer genomics and diagnostics, and microscopic colitis.

Paul B. Chapman has published multiple papers in various high-impact venues. Notable recent publications include:

  • Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade (2020, Journal of Clinical Oncology)
  • The State of Melanoma: Emergent Challenges and Opportunities (2021, Clinical Cancer Research)
  • LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade (2021, Science Translational Medicine)
  • Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials (2020, European Journal of Cancer)
  • Immune Checkpoint Inhibitor-Associated Optic Neuritis (2020, Ophthalmology)

The venues where Paul B. Chapman's work frequently appears highlight their focus on clinical oncology and cancer research. These include:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • Melanoma Research
  • Gastroenterology

Collaboration forms a significant part of their research activities. Frequent co-authors with whom Paul B. Chapman has worked include:

  • Alexander N. Shoushtari
  • Jedd D. Wolchok
  • Michael A. Postow
  • Margaret K. Callahan
  • Parisa Momtaz

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

    Héctor Peinado;Maša Alečković;Simon Lavotshkin;Irina Matei

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

    Ravid Straussman;Teppei Morikawa;Kevin Shee;Michal Barzily-Rokni

  • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

    Poulikos I. Poulikakos;Yogindra Persaud;Manickam Janakiraman;Xiangju Kong

  • Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

    Troy Z. Horvat;Nelly G. Adel;Thu-Oanh Dang;Parisa Momtaz

  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

    Fei Su;Amaya Viros;Carla Milagre;Kerstin Trunzer

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • KIT as a therapeutic target in metastatic melanoma

    Richard D. Carvajal;Cristina R. Antonescu;Jedd D. Wolchok;Paul B. Chapman

  • Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

    Paul B. Chapman;Lawrence H. Einhorn;Michael L. Meyers;Scott Saxman

  • Evolutionary dynamics of cancer in response to targeted combination therapy

    Ivana Bozic;Johannes G Reiter;Benjamin Allen;Benjamin Allen;Tibor Antal

  • Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak

  • The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

    Eric W. Joseph;Christine A. Pratilas;Poulikos I. Poulikakos;Madhavi Tadi

  • Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival

    Geoffrey Y. Ku;Jianda Yuan;David B. Page;Sebastian E. A. Schroeder

  • Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

    Richard D. Carvajal;Jeffrey A. Sosman;Jorge Fernando Quevedo;Mohammed M. Milhem

  • Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells

    Dianna Y. Wu;Neil H. Segal;Stephane Sidobre;Mitchell Kronenberg

  • Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications

    Y.B. Su;Sejean Sohn;Susan E. Krown;Philip O. Livingston

Frequent Co-Authors

Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Katherine S. Panageas
Katherine S. Panageas Memorial Sloan Kettering Cancer Center
Richard D. Carvajal
Richard D. Carvajal Columbia University
Keith T. Flaherty
Keith T. Flaherty Harvard University
Alan N. Houghton
Alan N. Houghton Memorial Sloan Kettering Cancer Center
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Antoni Ribas
Antoni Ribas University of California, Los Angeles
David B. Solit
David B. Solit Memorial Sloan Kettering Cancer Center
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in healthcare goes beyond pursuing an MD. Many students look for alternative pathways and flexible online degree options to quickly enter the medical field. For example, online BSN programs for non nurses offer a fast-track route for those with a bachelor’s degree in another field to become registered nurses without starting over.

Not all nursing programs require the TEAS or HESI entrance exams—a big relief for some applicants. You can find nursing schools that don't require teas test, making the admission process smoother and less stressful.

For those interested in administrative roles, accelerated healthcare programs enable you to earn a healthcare administration degree online in less time than traditional options.

Additionally, coding and billing specialists are in high demand. For affordable entry, explore financial aid for medical billing and coding online classes. These programs offer quick certification and job-ready skills, making them a practical choice for career changers.

Best Scientists Citing Paul B. Chapman

Trending Scientists

Recently Published Articles